PR Newswire Clinical TrialsOriginal article
Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
PartnershipZegfrovyPositive
AI Analysis
Summary
Dizal granted AstraZeneca worldwide exclusive rights to develop and commercialize Zegfrovy, with Dizal receiving $600M upfront, up to $900M in milestone payments, and tiered royalties on global sales.
Outcome Details
Global exclusive license agreement for development and commercialization
Importance:7/10
Sentiment:
0.80
licensingpartnershipexclusive agreementupfront paymentmilestone paymentsroyalties
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 14, 2026 6:00 AM